Basic Information
Corporate Information [PDF: 376KB]
Company Name |
Mitsubishi Tanabe Pharma Corporation |
Capital Stock |
50 billion yen |
President&Representative Director |
UENO Hiroaki |
Headquarters |
3-2-10, Dosho-machi, Chuo-ku, Osaka 541-8505, Japan TEL: 81-6-6205-5085 |
Incorporated |
December 13, 1933 |
Date of Merger |
October 1, 2007 |
Business Activities
Pharmaceuticals
Manufacture and sale of pharmaceuticals, centered on ethical drugs
Major Ethical Drugs
Immuno-inflammation
Remicade |
agent for treatment of rheumatoid arthritis, Crohn’s disease, Bechet’s disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, ulcerative colitis and Kawasaki disease |
Simponi |
agent for treatment of rheumatoid arthritis and ulcerative colitis |
Stelara |
agent for treatment of Crohn’s disease |
Imusera |
agent for treatment of multiple sclerosis |
Diabetes and kidney
Tenelia |
agent for treatment of type Ⅱ diabetes mellitus |
Canaglu |
agent for treatment of type Ⅱ diabetes mellitus |
Canalia |
agent for treatment of type Ⅱ diabetes mellitus |
Central nervous system
Lexapro |
anti-depressant agent |
Radicut |
cerebral neuroprotectant |
Other
Rupafin |
agent for treatment of allergic disorders |
Vaccines
Influenza |
|
TETRABIK |
combined vaccine for diphtheria, pertussis, tetanus and poliomyelitis (polio) |
Varicella vaccine |
|
JEBIK V |
vaccine for Japanese encephalitis |
Major OTC Products
- Flucort f (agent for treatment of skin conditions)
- Cort f series (agent for treatment of skin conditions)
- Tanabe ichoyaku〈choritsu〉(digestive medicine)
- Tanabe ichoyaku urso (digestive medicine)
- Urso ukon (digestive drink)
- Cerekinon S (digestive medicine)
- Aspara drink α (nutrient and tonic drink)